WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Lung Cancer efficacy endpoints v4, -cough -shortness of breath -chest pain -fatigue -other specifying severity, Karnofsky with allowed values 0, 10, 20...100, Therapeutic Efficacy Endpoint is intersection of Therapeutic Intervention, Sponsor specified Response Criteria (e.g. RECIST) has_component Follow-up evaluation, Short axis for target lymph nodes measured in mm, -Complete Response (CR) -Non-CR/non-PD -Not evaluated -Not all evaluated -Non-PD -PD -Unequivocal PD -Any summarized into OVERALL RESPONSE, Baseline assessment summarized_by Non-measurable lesions, Informational or proposed for removal concepts identified by grey color boxes, LD (axial plane) for target lesion measured in mm, Duration of response measured at Date of tumor progression, Time to progression of cancer symptoms includes Name of the PRO instrument, Progression free survival (PFS) measures Tumor Response, Objective Response Rate (ORR) measured at Date of initial response, Follow-up evaluation summarized_by Measurable lesions, Sum of longest diameters (SLD) has_component LD (axial plane) for target lesion, Non-target lesion have response options -Complete Response (CR) -Non-CR/non-PD -Not evaluated -Not all evaluated -Non-PD -PD -Unequivocal PD -Any, Concepts are denoted by solid round-edged rectangle, Anatomical region include most common -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, Lung Cancer Efficacy Endpoints include Time to progression of cancer symptoms, Objective Response Rate (ORR) measured at Date of tumor progression